Evan Loh climbs the ladder to become CEO at Paratek Pharmaceuticals; Codiak's Doug Williams takes chairman's role at AC Immune
→ Determined to be the good story that the antibiotics field so desperately needs, Paratek Pharmaceuticals $PRTK is reshuffling its top-level management to handle a growing commercial operation. Evan Loh has become CEO after climbing the ladder over the past seven years (from CMO to president and COO) while Michael Bigham claims the newly created position of executive chairman. They will oversee life cycle expansion initiatives for Nuzyra with chief commercial officer Adam Woodrow, who’s been promoted to president. Meanwhile, Randy Brenner will take up additional responsibilities in medical affairs after leading the regulatory efforts for Paratek.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.